Corporate Profile
vTv Therapeutics (vTv) is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes (T1D)*.
Corporate Presentation
Stock Quote & Chart
Change
52 Week High
52 Week Low
Minimum 15 minutes delayed. Source: LSEG
*Cadisegliatin is under investigation and the safety and efficacy has not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.